Stock Analiz

Oncolytics Biotech Inc. ONCY

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.37Market cap $49M
Open the interactive analysis →

Oncolytics Biotech Inc. (ONCY) is a healthcare company listed in the US with a market value of about $49M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -184%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Oncolytics Biotech

Oncolytics Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-41.5%
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-184.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue————$0$0$0$401869$5M—
Net income-$29M-$23M-$21M-$18M-$21M-$18M-$25M-$13M-$12M-$11M
Free cash flow-$20M-$20M————————
EPS (diluted)$-0.22$-0.17$-0.16$-0.14$-0.16$-0.13$-0.19$-0.10$-0.10$-0.09
Net margin———————-3110.7%-252.6%—
ROIC—-497.1%-102.8%-80.3%-57.4%-102.9%—-220.2%-148.8%-113.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $4.43, 1097% above the current price; targets range from $2.84 to $5.83; the consensus rating is “Buy”; expected EPS is $-0.38 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Oncolytics Biotech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Oncolytics Biotech pay a dividend?

Not currently.

Is Oncolytics Biotech a good stock to buy?

We do not give buy or sell advice. Oncolytics Biotech scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.